Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

not_yet_recruiting125%
completed250%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

NCT05517447
not_yet_recruiting

Clonal Hematopoiesis of Immunological Significance

NCT05969821
completed

Integrated Discovery and Development of Innovative TB Diagnostics

NCT06624501
completed

No Association Between Vitamin C and E Supplementation, Frailty, and Grip Strength Over Five Years: The CoLaus Study

NCT03258970

Clinical Trials (4)

Showing 4 of 4 trials
NCT05517447Phase 3

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Terminated
NCT05969821

Clonal Hematopoiesis of Immunological Significance

Not Yet Recruiting
NCT06624501

Integrated Discovery and Development of Innovative TB Diagnostics

Completed
NCT03258970

No Association Between Vitamin C and E Supplementation, Frailty, and Grip Strength Over Five Years: The CoLaus Study

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4